Quercefit®
浏览有关 Indena 产品、活动、公司信息等的所有文档。
前往查看
See through science
Quercefit®
滚动查看更多
PEER-REVIEWED SCIENCE ON QUERCEFIT®
Fatigue? The answer is Quercefit®
A double-blind, randomized, placebo-controlled clinical study recruited 78 individuals with fatigue to evaluate the positive effects of administering Quercefit® (500 mg/day) on self-reported fatigue levels, sleep quality, and physical performance after a 2-month period from the baseline visit.
Data from the treatment group showed significant improvements in all parameters measured, including the FIS-40 scale (fatigue score), PSQI scale (sleep quality), and SPPB test (physical performance), compared to both the baseline and the placebo group (Figure 1).
Figure 1: Variation of FIS-40, PSQI and SBBP in placebo group and treatment group vs baseline, after 2 months of treatment. *p<0.0001 vs placebo; ** p<0.001 vs placebo; ***p<0.001 vs placebo.
Is this the beginning of a natural approach?2
The administration of Quercefit® for a three-month period has been correlated with a favorable modulation of the body’s physiological response to symptomatic Covid-19 (Figures 2, 3).
This stems from the results of a single-center, prospective, randomized, controlled cohort study that enrolled a total of 120 healthcare workers (not vaccinated and taking all virus containment measures) randomized into two groups (60 subjects each), supplementing respectively with Quercefit® (250 mg twice a day) or a placebo.
Figure 2: Survival without Covid-19 during follow-up time between groups.
Figure 3: Conditions assessed by NEWS in subjects exposed to Covid-19.
Help from nature3,4
The administration of Quercefit® as diet supplementation showed positive effects in another study: of the 5 subjects who contracted Covid-19, there was only 1 out of the 60 in the quercetin Indena Phytosome™ group and 4 out of 60 in the control group. Complete clinical remission was recorded at 7 and 15 days in the supplementation and placebo groups, respectively.
These data were obtained during a prospective, randomized, controlled, open-label study in which 152 subjects were enrolled and randomized in two groups treated respectively with standard care or standard care plus Quercefit® (500 mg twice a day).3
A second clinical trial confirmed the benefits of diet supplementation with quercetin. The results showed that subjects who received Quercefit® (n= 21) had better outcomes compared to the ones receiving standard care.4
All data confirmed for Quercefit®5
These data were validated thanks to the completion of an initial clinical study now extended to 100 Sars-CoV-2-positive subjects that received standard care either alone or with Quercefit® as add-on supplementation (500 mg 3 times a day for the first week; 2 times a day for the second). The results confirmed that subjects who received standard care plus Quercefit® recovered faster and were in better health compared to the control group.5
Indeed, 68% of the subjects who received quercetin supplementation recovered faster from the virus (within one week), compared to 24% in the control group (Figure 3). Moreover, individuals following the Quercefit® regimen had weaker symptoms and showed a better biomarker profile (reduction of LDH) within a week. These data are also complemented by the confirmation of the product’s good tolerability.5
Figure 4: Subjects’ follow-up RT-PCR COVID-19 test results in the two groups.
Improvements in allergy-related discomforts and quality of life6
Repeated oral intake of a Quercefit®-containing supplement for 4 weeks has been shown to reduce allergy-related symptoms such as eye itching, sneezing, nasal discharge and sleep disorders compared to the placebo group (n=66).6
Moreover, the treated group also experienced improved quality of life, as reported in the chart below (Figure 5). 6
Figure 5: Total score of the Japanese Rhino-conjunctivitis Quality of Life Questionnaire in the two groups, before starting supplementation (baseline), and 2 and 4 weeks later. Graphic representation of ref.1 table III.
Allergic conjunctivitis? Try Quercefit® as complementary treatment7
Confirming its beneficial role for ocular allergy-related disorders, a study performed on adults affected by allergic conjunctivitis showed that Quercefit® may potentially be the perfect natural aid to avoid clinical worsening. In particular, an analysis on 15 subjects after 15 days of supplementation (250 mg, twice a day) highlighted significant improvements in terms of Total Ocular Symptoms Score (TOSS) (Figure 6).7
Figure 6: TOSS score before and after 15 days of Quercefit® supplementation.
Where it helps: allergy-prone subjects8
Quercefit® shows a potential promising effect during allergy season. A further study confirms that after 30 days, administration optimizes general wellbeing in allergy-prone subjects and modulates rhinitis, in addition to reducing the frequency of intermittent discomforts up to 50% during the day and up to 70% during the night.8
Prompt wellbeing restoration for injured eyes9
A series of 8 case studies have confirmed that Quercefit® can be the perfect ally for eye health, during topical antibiotic therapy on damaged ocular tissues (Figure 7).
Figure 7: Corneal condition following misuse of soft daily contact lenses, before (a) and after (b) supplementation.
直奔主题1
Quercefit®的槲皮素溶解度提高了 1倍，进而使 Quercefit®的生物利用度提高了 20倍，并且能够以较低的剂量使用，同时提供与富含蔬菜和水果的饮食水平一致的槲皮素摄入量。 根据一项针对 12名参与者（18-50岁）的试验，口服一剂普通的槲皮素（500毫克）、250毫克 Quercefit®和 500毫克 Quercefit®，Quercefit®组的血浆槲皮素水平更高。
图 1：摄入普通槲皮素（白点）、Quercefit® 250 mg（灰点）和 Quercefit® 500 mg（黑点）后，槲皮素血浆浓度 (ng/ml)的时间变化。
与众不同之处：运动营养2
在对 48名非专业铁人三项运动员进行的一项试验中，Quercefit®显示出对训练和表现的积极影响。 Quercefit®给药组比未给药组跑得更快（-11.3% vs. -3.9%）。同样，Quercefit®可以改善跑步后的肌肉不适和痉挛以及运动后的恢复时间，并且还可以平衡氧化应激。
图 2：Quercefit®给药组和未给药组中的血浆自由基 (PFR)单位。
有帮助的地方：易过敏的人群4
Quercefit®在过敏时代显示出潜在的保护作用。 Quercefit®给药30天后，可优化易过敏受试者的总体健康状况，并调节鼻炎评分。 30天后，Quercefit®组白天间歇性不适频率减少高达 50%，夜间间歇性不适频率减少高达 70%。
参考文献
1 Rondanelli M. et al.; Biomedicine & Pharmacotherapy 167 (2023): 115453.
2 Rondanelli M. et al.; Life (2022).
3 Di Pierro F. et al.; Int J Gen Med 14 (2021):2359.
4 Di Pierro F. et al.; Int J Gen Med 14 (2021):2807-2816.
5 Di Pierro F. er al; Frontiers in Pharmacology (2023).
6 Yamada, S. et al. European review for medical and pharmacological sciences (2022) 4331–4345.
7 Mazzolani et al.; Austin of allergy (2022).
8 Cesarone, M. R., et al.; Minerva medica (2019).
9 Mazzolani et al.; International Journal of Case Studies in Clinical Research (2022); Volume 6 Issue 3: 10-19.
10 Riva A. et al.; Eur J Drug Metab Pharmacokinet (2018).
11 Riva A. et al.; Minerva Medica (2018); 109(4):285-9.
